During Prime Minister’s Questions, the Prime Minister described the investment as a “major vote of confidence in the UK and Labour’s plans to strengthen our economy.”
The investment, made possible through a new pharmaceutical agreement with the United States, will help secure and futureproof thousands of high-skilled UK jobs, including in Cambridge, one of the UK’s leading global hubs for life sciences and innovation.
The announcement represents a significant boost for Cambridge’s world-class research ecosystem and underlines the success of Labour’s strategy to drive growth through innovation and long-term investment.
The investment further cements Cambridge’s position as a key driver of economic growth, supporting cutting-edge research, attracting global talent, and reinforcing the UK’s leadership in life sciences.
Daniel Zeichner MP said: “This £300 million investment is fantastic news for Cambridge and our world-leading life sciences sector. Our city is at the forefront of scientific discovery, and this commitment will help secure high-quality jobs and drive innovation for years to come. It demonstrates the strength of our local economy and the opportunities that come from backing science and innovation.”
